The psychiatry field is buzzing with anticipation — and hesitation — about esketamine for depression

The Food and Drug Administration is expected to decide in the coming weeks whether to approve esketamine, which would become the first major depression treatment to hit the market in decades. The psychiatry field is buzzing with excitement — and hesitation.